EVLO OTC
Evelo Biosciences, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -80.0%
1Y: -80.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$108M
+6.0% ▲
Net Income
-$115M
+6.3% ▲
EPS (Diluted)
$-26.28
+43.1% ▲
EBITDA
-$106M
+7.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $40M | $63M | $70M | $84M | $79M |
| SG&A Expenses | $18M | $23M | $22M | $32M | $30M |
| Operating Expenses | $58M | $86M | $92M | $115M | $108M |
| Operating Income | -$58M | -$86M | -$92M | -$115M | -$108M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $2M | $1M | $2M | $4M | $5M |
| Income Before Tax | -$57M | -$85M | -$93M | -$122M | -$114M |
| Tax Expense | -$3M | $190K | $409K | $428K | $930K |
| Net Income | -$54M | -$86M | -$94M | -$122M | -$115M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-49.25 | $-53.49 | $-47.45 | $-46.18 | $-26.28 |
| EBITDA | -$58M | -$84M | -$90M | -$115M | -$106M |
| Shares Outstanding | 1M | 2M | 2M | 3M | 4M |